Why the study?
Amino acid changes in foot-and-mouth disease virus VP1 alter viral properties and modulate host interferon signal transduction, prompting investigation into how these variations evade host immunity via MAVS/TRAF3-mediated responses.
The E83K mutation in FMDV VP1 attenuates the virus by preventing its ability to block MAVS/TRAF3-mediated type-I interferon signaling.
VP1 E83K mutation attenuates FMDV by impairing MAVS-mediated IFN suppression; leaves open targeted attenuation strategies for vaccine development.
VP1, a pivotal capsid protein encoded by the foot-and-mouth disease virus (FMDV), plays an important role in receptor-mediated attachment and humoral immune responses. Previous studies show that amino acid changes in the VP1 protein of cell culture-adapted strains of FMDV alter the properties of the virus. In addition, FMDV VP1 modulates host IFN signal transduction. Here, we examined the ability of cell culture-adapted FMDV VP1(83K) and wild-type FMDV VP1(83E) to evade host immunity by blocking mitochondrial antiviral signaling protein (MAVS)/TNF Receptor Associated Factor 3 (TRAF3) mediated cellular innate responses. Wild-type FMDV VP1(83E) interacted specifically with C-terminal TRAF3-binding site within MAVS and this interaction inhibited binding of TRAF3 to MAVS, thereby suppressing interferon-mediated responses. This was not observed for cell culture-adapted FMDV VP1(83K). Finally, chimeric FMDV harboring VP1(83K) showed very low pathogenicity in pigs. Collectively, these data highlight a critical role of VP1 with respect to suppression of type-I IFN pathway and attenuation of FMDV by the E83K mutation in VP1.
No takes yet. Share an insight, caveat, or question.
Ekanayaka et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: